

## ASX ANNOUNCEMENT

### CELLMID SHARE PURCHASE PLAN COMPLETED

**SYDNEY, Friday, 1 May 2020: Cellmid Limited (ASX: CDY)** advises that the Share Purchase Plan ("SPP") announced on 7 April 2020 with an offer price of \$0.22 has now closed.

The Company received applications to the value of \$302,999.84 for the issuing of 1,377,272 shares. The SPP was offered at the same price as the share placement to sophisticated and institutional investors for \$6 million, also announced on 7 April 2020. The Company expects the shares under the SPP to be allotted on or around 4 May 2020.

The \$6.3 million raised under the share placement and the SPP will be used to fund the roll out of the SARS-CoV-2 diagnostics tests and general working capital.

Cellmid CEO, Maria Halasz said, "We thank our existing shareholders for their continued support through this SPP and welcome the new shareholders that joined us through the placement."

Approved for release by the Board of Directors.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

#### **Cellmid Limited (ASX: CDY)**

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. For further information, please see [www.cellmid.com.au](http://www.cellmid.com.au) and [www.evolisproducts.com.au](http://www.evolisproducts.com.au). Cellmid's wholly owned subsidiary, Lyramid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Most recently, the Company commenced sale of a point of care antibody test for SARS-CoV-2 .

#### **Forward looking statements**

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.